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On 31 October 2000, the Food and Drug Administration 
(FDA), Center for Veterinary Medicine (CVM) 
proposed to withdraw approval for the fluoroquinolone 
enrofloxacin for poultry (marketed under the trade- 
name Baytril 3.23% Concentrate Antimicrobial Solu- 
tion). Baytril was licensed by the CVM in 1996 for use 
in treating life-threatening diseases in turkeys and 
chickens. This proposal was based in part on concern 
that the use of Baytril in poultry may have resulted in 
an increase in human fluoroquinolone-resistant Campylo- 
batter infections, which could reduce the effectiveness 
of fluoroquinolones in treating campylobacteriosis in 
humans.‘s2 
Bayer evaluated the data presented by the CVM, 
and consulted experts in microbiology, and veterinary 
and human medicine. As a result of its scientific 
evaluation of the data, Bayer concluded that the con- 
tinued use of Bayril in poultry did not have an adverse 
human health impact. On 21 February 2001, Bayer 
presented its data and conclusions to the FDA, and 
requested that the FDA grant a hearing on its proposed 
withdrawal of Baytril. 
Bayer understands and supports the CVM’s mission 
to protect public health, and appreciates the difficulty 
of determining the cause of a reported increase in 
Campylobacter fluoroquinolone resistance. Bayer also 
believes that it is important to identify the causes of 
resistance to fluoroquinolones in Campylobacter, and to 
quantify the attributable risks so that targeted appro- 
priate mitigation measures can be applied. 
In 2002, Bayer assembled experts in poultry pro- 
duction and medicine, resistance monitoring, Campylo- 
batter epidemiology and genetics, and risk assessment, 
and physicians involved in the diagnosis and treatment 
of human infectious diseases, to discuss the use of 
fluoroquinolones in poultry and its potential impact. The 
symposium was convened for the purpose of providing 
a scientific forum to examine the effects of the use 
of Baytril in poultry on the development of fluoro- 
quinolone-resistant Campylobacter, and to evaluate the 
potential human health consequences of such use. 
CONCLUSIONS 
Campylobacter jejuni is currently the second most 
commonly recognized cause of bacterial gastroenteritis 
in humans in the USA. When antibiotics are indicated 
for the treatment of Campylobacter gastroenteritis, 
erythromycin or a fluoroquinolone such as ciprofloxacin 
is considered the drug of choice. Fluoroquinolones 
are frequently prescribed empirically for diarrhea1 
illness, including travelers’ diarrhea, because of their 
effectiveness against a range of enteric bacteria. Since 
the late 1980s the resistance of Campylobacter isolates 
to fluoroquinolones has been increasing, especially in 
Europe and in certain South American countries. Poultry 
have traditionally been considered to represent a major 
source of Campylobacter infections in humans, and 
some investigators have proposed a causal relationship 
between the use of fluoroquinolones in animals and the 
increase in fluoroquinolone-resistant Campylobacter 
infections in humans. The majority of Campylobacter 
infections occur as sporadic individual infections. 
The objective of the symposium was to examine the 
evidence that the use of fluoroquinolones in poultry 
health management contributes to the emergence of 
fluoroquinolone-resistant Campylobacter species that 
may be transferable to humans, resulting in an increase 
in human fluoroquinolone-resistant Campylobacter in- 
fections, thus reducing the effectiveness of fluoroquino- 
lones in treating campylobacteriosis in humans. 
The current rate of fluoroquinolone resistance 
among human isolates in the USA is <15%, similar 
to a level noted in 1995, prior to the introduction of 
enrofloxacin for the treatment of confirmed poultry 
disease. It is important to note that < 1% of all poultry 
in the USA are treated with enrofloxacin annually, which 
is a much lower rate than that of human quinolone 
administration in the same country (~40 million adults 
received a quinolone in 2001, representing 210% of 
the US population). 
The fully integrated system of poultry production 
in the USA is characterized by the rearing of large 
numbers of birds under intensive conditions, which 
requires excellent animal health management veterinary 
services. When certain bacterial diseases occur in a 
population of broiler chickens, the veterinarian must 
diagnose the disease correctly, and select an antibiotic 
which will be cost-effective and will not result in illegal 
drug residues. Enrofloxacin is the most effective anti- 
microbial available for the treatment of airsacculitis in 
poultry production. Although it may be used empirically 
based on clinical experience, a definitive diagnosis based 
on necropsy, culture and susceptibility testing is the 
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procedure employed by poultry veterinarians in the 
majority of cases. 
The CVM’s proposal to withdraw approval for 
enrofloxacin for poultry was based in part on concern 
that use of the drug in poultry may have resulted in an 
increase in human fluoroquinolone-resistant Campylo- 
batter infections (data derived from national surveillance 
sources), which could reduce the effectiveness of fluoro- 
quinolones in treating campylobacteriosis in humans. 
A review of the United States National Anti- 
microbial Resistance Monitoring System (NARMS) 
data on fluoroquinolone-resistant Campylobacter isolates 
from humans with campyiobacteriosis revealed no 
evidence to indicate a rise in resistant isolates associated 
with the introduction of the use of fluoroquinolones in 
poultry. A number of shortcomings in the NARMS 
program include a lack of overall sampling design, biases 
in the collection of isolates from animal samples, non- 
compliance of state departments of health with NARMS 
protocols, lack of such basic data as genotype infor- 
mation of the organisms isolated, and, for animal 
samples, lack of measurements of bacterial load. When 
combined, these inadequacies indicate that the present 
NARMS data probably overestimate the resistance 
levels, and do not provide reliable information with 
which to quantify the extent and temporal trends of 
antimicrobial resistance in Campylobacter and other 
enteric bacteria from human and animal populations. 
The NARMS system is useful as a qualitative monitor- 
ing system which can provide an indication of emerging 
resistance, but in its present form is not useful as a 
quantitative tool. 
In order to support the CVM proposal, it is essential 
that specific and reliable methods of proving relatedness 
of isolates be available. Genotyping methods are used to 
differentiate Campylobacter jejuni isolates. However, 
the data are complex and do not support simple models 
of transmission. Several observations have apparently 
weakened their value and complicated the interpre- 
tation of genotyping methods. The epidemiologic tools 
currently available to demonstrate the transmission of 
Campylobacter strains from poultry to humans, and that 
poultry represent the source of the disease, are in- 
adequate. The relatively small number of fluoroquino- 
lone-resistant strains further highlights the likelihood 
that drug-resistant disease may be uncommon and 
therefore difficult to establish a clear causality for. The 
measurement of resistance in poultry and human isolates 
using one single phenotyping or genotyping method to 
prove identity of clones is insufficient to conclude that 
particular resistant strains isolated from humans and 
poultry are identical. 
Campylobacter jejuni, and its close relative C. coli, 
are Gram-negative thermophilic, microaerophilic bac- 
teria that colonize the intestinal mucosa of various 
hosts and are considered to be ubiquitous in the general 
environment. Humans may become infected from 
poultry and other contaminated meats, and from water 
contaminated with feces from livestock, wild animals, 
birds, and other humans. The organism cycles in the 
environment through all potential hosts. Campylobacter 
species have been isolated from the feces of dogs with 
and without diarrhea.3 The outcome of host colonization 
is variable. Evidence suggests that the organisms have 
evolved to preferentially and chronically colonize a 
relatively unique niche in the avian gut as a commensal. 
Infection in most animals, and many humans, is also 
asymptomatic and transient. However, infection in 
susceptible humans may lead to an acute but self-limit- 
ing enteritis. There are several possible explanations for 
such a range of outcomes, including the host immune 
status and variations in bacterial virulence, particularly 
invasiveness and toxin production. There is also 
increasing evidence that the bacterium can respond to 
its host environment during growth in the host intestine 
by switching on gene expression and possibly by genetic 
rearrangement. 
Relevant to this symposium, in a recent publication 
the fluoroquinolone-resistant strains of Cumpylobacter 
from human clinical sources and chickens originating in 
Northern Ireland were compared.4 The study was largely 
self-contained, because most of the poultry consumed 
had been produced locally and there was relatively little 
foreign travel. Overall, there were no isolates from either 
source which shared complete phenotypic homology. 
A high degree of phenotypic diversity was observed 
among the biotypes from chickens and humans, with 
only two common biotypes. The prevalence of antibiotic- 
resistant organisms was similar in both humans and 
chickens, with the exception of a higher rate of tetra- 
cycline resistance in chickens. Fluoroquinolone resistance 
was higher in the human isolates than in the animal 
isolates. This higher level of fluoroquinolone resistance 
in human isolates possibly suggests acquisition from 
another source, where fluoroquinolones are more 
frequently used than in poultry production, e.g. small 
animals and pets. A small proportion of human in- 
fections are reportedly acquired from dogs. The study 
illustrated the difficulty in deducing the origins of 
fluoroquinolone resistance in campylobacters, which may 
come not only from poultry but also from other animal 
sources, especially domestic pets, in addition to human 
sources. 
Analysis of case-control data on campylobacteriosis 
in humans revealed that fluoroquinolone resistance in 
human isolates is not positively associated with the 
consumption. of chicken. According to the CDC data, 
chicken consumed at home appears to be protective 
against campylobacteriosis. Even handling and pre- 
paring chicken at home seems to be associated with a 
decreased risk of campylobacteriosis. This poses the 
question of whether chicken really is a common source 
of infective doses to people. If chicken by itself is 
not transmitting Campylobacter to humans, then it is 
probably not transmitting fluoroquinolone-resistant 
Campylobacter to people. The CDC’s own studies 
illustrate the wide range of other potential sources of 
Campylobacter infections. 
The CDC data also indicate that restaurant dining 
is significantly associated with Campylobacter risk in the 
USA, and Campylobacter-shedding restaurant workers 
have been identified as the source of Campylobacter 
outbreaks in the USA and Brazil. If restaurant workers 
represent an important source of Campylobacter, then 
fluoroquinolone resistance profiles in workers may 
influence fluoroquinolone resistance patterns in the 
population at large. This suggests that risk management 
strategies which focus on restaurant kitchen hygiene 
rather than on chickens may be more productive in 
preventing human campylobacteriosis and other intestinal 
infections. Attempts to reduce fluoroquinolone-resistant 
Campylobacter isolates among human campylobac- 
teriosis patients by banning fluoroquinolone use in 
chickens may be unsuccessful, because there does not 
appear to be an incontrovertible causal link. 
It is estimated that there are over 200 000 000 
episodes of acute enteritis annually in the USA, of which 
approximately 75 000 000 are foodborne. Fewer than 
20% of the estimated cases have a known etiology. 
Nearly half of the more than 4 000 000 cases of known 
foodborne bacterial enteritis are attributed to Cumpylo- 
batter infections. The FoodNet active population-based 
surveillance system has demonstrated geographic 
variation in the incidence of Campylobacter infection, 
and the incidence of Campylobacter infections has been 
generally declining in the USA since 1996. C. jejuni 
infections may vary in severity and duration, and 
symptoms may persist for more than 1 week in 20% of 
patients. Antimicrobial therapy, especially if administered 
early, is thought to hasten clinical resolution by 2-3 
days. Therapy is generally restricted to individuals with 
moderate-to-severe disease, and high-risk individuals, 
e.g. those with underlying immunodeficiency, extremes 
of age, or chronic illness. Approximately lo-15% of C. 
jejuni isolates exhibit in vitro resistance to fluoroquino- 
lones, although most strains are susceptible to macro- 
lides. 
In 2001, Campylobacter was the second most 
frequent foodborne pathogen, with Salmonella being 
the most common, isolated from humans in Germany. 
Epidemiologic risk factors include consumption of 
poultry and untreated milk, and contact with surface 
water. Travel plays an important role, especially in 
Scandinavia, the UK, and certain states in the USA, 
where a high proportion of Campylobacter isolates 
of human infections are imported. Such isolates are 
much more often resistant to fluoroquinolones than are 
domestic strains. Fluoroquinolone resistance in human 
Campyfobacter isolates is lowest in the UK and 
Denmark, at 12%. Estimates of resistance range from 
20% to 40% in Finland, The Netherlands, Norway, 
Sweden, Austria, and Germany, with peaks of 70-SO% in 
Spain. Usually, uncomplicated Campylobacter enteritis 
is symptomatically treated. If, in severe cases, anti- 
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microbials are indicated, in all European countries except 
Switzerland macrolides are used as first-line drugs, 
followed by fluoroquinolones or doxycycline. 
In summary, the available evidence does not con- 
clusively support the hypothesis that the veterinary use 
of fluoroquinolones in poultry in the USA has resulted 
in fluoroquinolone-resistant Campylobacter strains that 
were transmitted to people, causing disease in those 
people, and resulting in compromised treatment. The 
weight of evidence is insufficient to indicate that the 
therapeutic use of fluoroquinolones in poultry is a 
significant risk to public health and thus requires 
withdrawal of the approval of enrofloxacin for use in 
poultry in the USA. The symposium provided evidence 
that the increased risk of campylobacteriosis in humans 
is significantly associated with food prepared outside the 
home and not with chicken cooked at home. Proper 
handling and cooking of food can almost entirely 
eliminate the risk from C. jejuni.” It appears unlikely 
that eliminating the use of fluoroquinolones in chickens 
would have any detectable human health benefit in 
reducing the incidence of resistant Campylobacter 
infections in humans. Nothing in the scientific data or 
the previously published data from various state and 
national studies examined suggests that the use of 
fluoroquinolones to treat chickens consumed in the 
USA is a risk to public health. A similar finding in 
northern Europe has recently been reported by de 
Neeling et al6 who examined the possible relationship 
between fluoroquinolone resistance in Campylobacter in 
poultry and humans. Clear evidence showing that 
antibiotic-resistant bacteria arising in animals cause 
subsequent infection in humans which is then difficult to 
treat is difficult to find. Fluoroquinolone-resistant 
salmonellae and Campylobacter have been isolated 
from animals, foodstuffs, and humans, although evidence 
showing the full sequence of events, including the 
compromise of antibiotic choice by the clinician, has not 
yet been published.’ 
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